Purdue will pay out millions in bonuses in bankruptcy case

Amy Baxter | September 20, 2019 | Health Exec | Policy & Regulations

Researchers found millions of heart failure patients who qualify for standard, guideline directed medical therapies, but did not receive it due to poor health literacy, limited access to care and medication costs.

Purdue Pharma, maker of the popular opioid OxyContin, will be allowed to dole out millions of dollars in bonuses to executives as the company declares bankruptcy as part of a $10 billion settlement to resolve thousands of lawsuits against the company for its role in the national opioid abuse and overdose epidemic.

Specifically, the company will pay about $26 million in wages, benefits and bonuses, according to CNN.

Bankruptcy proceedings for Purdue began on Tuesday, Sept. 17, with a final hearing held on Oct. 10. Once the filings are complete, Purdue will provide more than $10 billion in funding to address the opioid crisis and the Sackler family, which owns the company, will cough up about $3 billion of their own fortune, CNN reported.

See the full story below:

Opioid-maker Purdue Pharma is allowed bonus payout in bankruptcy case

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

Cardiovascular Business

Payment cuts and beyond: Key takeaways for cardiologists from the 2025 Medicare Physician Fee Schedule

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals.

AI in Healthcare

A modest proposal to rally AI regulators around a simple game plan

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

Cardiovascular Business

FDA commissioner urges clinicians to join fight against medical misinformation

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

Purdue will pay out millions in bonuses in bankruptcy case

Related Content

Around the web